Zanidatamab monotherapy induces response in biliary tract cancers

Zanidatamab monotherapy appeared active among patients with HER2-amplified and -expressing biliary tract cancer, according to the agent’s manufacturer.Zanidatamab (Zymeworks) is an investigational bispecific antibody that can simultaneously bind two non-overlapping epitopes of HER2.The open-label, single-arm phase 2b HERIZON-BTC-01 trial investigated zanidatamab as monotherapy for patients with previously treated HER2-amplified and expressing biliary tract cancers.Confirmed ORR by independent central review served as the primary endpoint. Secondary endpoints included duration ofRead More

Generated by Feedzy